Cormorant Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Cormorant Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-850,000	Closed	-$20.2M	–	64
2023 Q2	$20.2M	Hold	850,000	–	–	1.13%	25
2023 Q1	$21.6M	Sell	850,000 -250,000	-23%	-$8.02M	1.42%	19
2022 Q4	$32.1M	Sell	1,100,000 -210,000	-16%	-$4.84M	2.15%	13
2022 Q3	$26.9M	Buy	1,310,000 +432,500	+49%	+$7.78M	1.88%	20
2022 Q2	$10.2M	Sell	877,500 -122,500	-12%	-$1.65M	0.77%	40
2022 Q1	$18.5M	Buy	1,000,000 +700,000	+233%	+$13.4M	1.42%	21
2021 Q4	$5.93M	Sell	300,000 -42,562	-12%	-$793K	0.35%	53
2021 Q3	$5.63M	Sell	342,562 -400	-0.1%	-$5.87K	0.23%	66
2021 Q2	$6.27M	Sell	342,962 -116,182	-25%	-$1.99M	0.21%	76
2021 Q1	$7.67M	Buy	459,144 +366,018	+393%	+$6.85M	0.17%	82
2020 Q4	$1.53M	Buy	+93,126	New	+$1.4M	0.04%	98

Other funds holding VRDN

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Cormorant Asset Management's VRDN Position: Q3 2023 in Review

Cormorant Asset Management sold out of Viridian Therapeutics (VRDN) in Q3 2023, closing a stake of 850,000 shares — an estimated $20.2M sold.

Cormorant Asset Management first reported a position in VRDN in Q4 2020 and held it in 11 quarters. The position peaked at $32.1M in Q4 2022. 123 funds tracked by Wall St. Rank hold VRDN as of Q3 2023.

Cormorant Asset Management reported no remaining Viridian Therapeutics position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 850,000 Viridian Therapeutics shares in Q3 2023, an estimated $20.2M.
Cormorant Asset Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 11 quarters.
Cormorant Asset Management's Viridian Therapeutics position peaked at $32.1M in Q4 2022.
123 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.